Authors : Paparkar Tanmayee Satish; Sadaphule Arti Laxman; Pratik Mondhe

Volume/Issue : Volume 10 - 2025, Issue 11 - November

Google Scholar : https://tinyurl.com/52c4yxfp

Scribd : https://tinyurl.com/jujd5x54

DOI : https://doi.org/10.38124/ijisrt/25nov700

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Pneumonia remains a significant global health concern, contributing to substantial morbidity and mortality across diverse patient populations. While antimicrobial therapy is the cornerstone of treatment, drug safety issues, such as adverse drug reactions (ADRs), antimicrobial resistance, and drug-drug interactions, pose critical challenges for optimal patient outcomes. Pneumonia is commonly treated with strong antibiotics, which can sometimes cause side effects in patients. This review combines hospital findings with research evidence to identify which drugs are more likely to cause adverse reactions. Most reactions were mild and improved with proper monitoring and timely changes in treatment. The study highlights the importance of pharmacovigilance in ensuring safe and effective pneumonia management. Pharmacovigilance plays a pivotal role in monitoring and evaluating these safety concerns, especially in varied demographic groups including children, older adults, immunocompromised individuals, and patients with comorbidities. This study examines post-marketing safety data related to pneumonia therapies, analyzing ADR trends, severity, and causality across demographic subgroups. Preliminary findings highlight age-related differences in susceptibility to ADRs, with elderly patients experiencing a higher incidence of cardiotoxic and nephrotoxic events, while pediatric populations exhibited more hypersensitivity reactions. Socioeconomic factors, polypharmacy, and genetic variability further influence drug safety profiles. These insights underscore the need for demographic-specific pharmacovigilance strategies and tailored prescribing practices to improve safety outcomes in pneumonia management. Enhanced real-world evidence generation, active ADR reporting, and integration of demographic-specific risk mitigation approaches are recommended to strengthen drug safety surveillance in pneumonia treatment. Doctors have several ways to check how serious pneumonia is, which helps them decide further care. Viruses can also cause pneumonia, so spotting them early is important to start the right treatment quickly. For community-acquired pneumonia, doctors usually recommend a combination of a beta-lactam antibiotic and a macrolide, or they may use a respiratory fluroquinolone on its own.

Keywords : Pneumonia, Pharmacovigilance, Adverse Drug Reactions, Antimicrobial Safety, Patient Demographics, Drug-Drug Interactions.

References :

1. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991 Feb 7;324(6):377-84. doi: 10.1056/NEJM199102073240605. PMID: 1824793. https://pubmed.ncbi.nlm.nih.gov/1824793/
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997 Jan 22-29;277(4):301-6. PMID: 9002492. https://pubmed.ncbi.nlm.nih.gov/9002492/
3. Strom BL, Tugwell P. Pharmacoepidemiology: current status, prospects, and problems. Ann Intern Med. 1990 Aug 1;113(3):179-81. doi: 10.7326/0003-4819-113-3-179. PMID: 2197907. https://pubmed.ncbi.nlm.nih.gov/2197907/
4. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994 Nov 10;331(19):1272-85. doi: 10.1056/NEJM199411103311906. PMID: 7794310. https://pubmed.ncbi.nlm.nih.gov/7794310/
5. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991 Feb 7;324(6):377-84. doi: 10.1056/NEJM199102073240605. PMID: 1824793. https://pubmed.ncbi.nlm.nih.gov/1824793/
6. http://www.egagenerics.com/gen.vigilenice.htm
7. Eileen G, Hollcend, Phevm D, Frank V, Degrig M. D. drug induced disorder. D. family Physician November. 1997;2:10. https://scholar.google.com/scholar_lookup?journal=D.%20family%20Physician%20November&title=D.%20drug%20induced%20disorder&author=G%20Eileen&author=%20Hollcend&author=D%20Phevm&author=V%20Frank&author=M%20Degrig&volume=2&publication_year=1997&pages=10&
8. McNamee D. Speaking about pharmacovigilance. Lancet. 1996 Oct 5;348(9032):908. doi: 10.1016/S0140-6736(05)65336-6. PMID: 8843807.  https://pubmed.ncbi.nlm.nih.gov/8843807/
9. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. PMID: 31573350; PMCID: PMC6812437. https://pubmed.ncbi.nlm.nih.gov/31573350/
10. Govindan S, Hyzy RC. The 2016 Guidelines for Hospital-acquired and Ventilator-associated Pneumonia. A Selection Correction? Am J Respir Crit Care Med. 2016 Sep 15;194(6):658-60. doi: 10.1164/rccm.201607-1447ED. PMID: 27463241; PMCID: PMC5439659. https://pubmed.ncbi.nlm.nih.gov/27463241/
11. Candel, F.J.; Salavert, M.; Basaras, M.; Borges, M.; Canton, R.; Cercenado, E.; Cilloniz, C.; Estella, A.; Garcia-Lechuz, J.M.; Garnacho Montero, J.; et al. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review. J. Clin. Med. 2023, 12, 6864. https://www.mdpi.com/2077-0383/12/21/6864
12. Haque M (December 18, 2019) Seasonal Incidence of Community-acquired Pneumonia: A Retrospective Study in a Tertiary Care Hospital in Kathmandu, Nepal. Cureus 11(12): e6417. doi:10.7759/cureus.6417 https://www.cureus.com/articles/25472
13. Grief SN, Loza JK. Guidelines for the Evaluation and Treatment of Pneumonia. Prim Care. 2018 Sep;45(3):485-503. doi: 10.1016/j.pop.2018.04.001. PMID: 30115336; PMCID: PMC7112285. https://pmc.ncbi.nlm.nih.gov/articles/PMC7112285/  
14. DRUG UTILISATION, ADVERSE DRUG REACTION PROFILE AND TREATMENT OUTCOME OF PNEUMONIA IN UNDER-FIVE CHILDREN IN A TERTIARY CARE HOSPITAL: A CROSS- SECTIONAL STUDY. March 2025 DOI:10.51168/sjhrafrica.v6i3.1717 https://www.researchgate.net/publication/391480165
15. Pathak AK, Kumar M, Dokania S, Mohan L, Dikshit H. A Retrospective Analysis of Reporting of Adverse Drug Reactions in a Tertiary Care Teaching Hospital: One Year Survey. J Clin Diagn Res. 2016 Aug;10(8):FC01-4. doi: 10.7860/JCDR/2016/18826.8284. Epub 2016 Aug 1. PMID: 27656459; PMCID: PMC5028501. https://pubmed.ncbi.nlm.nih.gov/27656459/
16. Lim WS. Pneumonia—Overview. Encyclopaedia of Respiratory Medicine. 2022:185–97. doi: 10.1016/B978-0-12-801238-3.11636-8. Epub 2021 Sep 17. PMCID: PMC7241411. https://pmc.ncbi.nlm.nih.gov/articles/PMC7241411/
17. Gao Z, Jiang Y, Zhang M, Luo C, Wei Z, Gong D, Wang G. Case Report: Drug-induced pneumonia caused by moxifloxacin and a literature review. Front Med (Lausanne). 2025 May 7;12:1467001. doi: 10.3389/fmed.2025.1467001. PMID: 40400635; PMCID: PMC12092464. https://pubmed.ncbi.nlm.nih.gov/40400635/
18. Dash, Snehasini & Panda, Suvendu & Behera, Jayanti & Mishra, Dr. (2025). DRUG UTILISATION, ADVERSE DRUG REACTION PROFILE AND TREATMENT OUTCOME OF PNEUMONIA IN UNDER-FIVE CHILDREN IN A TERTIARY CARE HOSPITAL: A CROSS- SECTIONAL STUDY. 3006-1059. 10.51168/sjhrafrica.v6i3.1717. https://www.researchgate.net/publication/391480165
19. Hassan MZ, Monjur MR, Biswas MAAJ, Chowdhury F, Kafi MAH, Braithwaite J, et al. Antibiotic use for acute respiratory infections among under-5 children in Bangladesh: a population-based survey. BMJ Global Health. 2021;6:e004010. https://doi.org/10.1136/bmjgh-2020-004010
20. K.M., M.A.A., and G. Kishore (2012) "Study of prescribing pattern of antibiotics in paediatric patients with pneumonia," Journal of Applied Pharmacy, 4, pp. 204-211. Available at: https://doi.org/10.21065/19204159.4.204.
21. SK, A. and Y, H. (2021) "Drug utilization study on paediatric pneumonia patients in a tertiary care teaching hospital," International Journal of Health Care and Biological Sciences, pp. 70-74. Available at: https://doi.org/10.46795/ijhcbs.v2i4.249.